Lutetium Lu 177 dotatate — Drug Monograph

Brand names: Lutathera

Drug class: Radiopharmaceutical

Mechanism of Action

A somatostatin-receptor-targeted radioligand therapy (peptide receptor radionuclide therapy, PRRT). The somatostatin analog DOTATATE binds with high affinity to somatostatin receptor subtype 2 (SSTR2), which is overexpressed on well-differentiated neuroendocrine tumors, and is internalized. The chelated β-emitting radionuclide lutetium-177 then delivers targeted ionizing radiation (tissue penetration ~2 mm) that causes lethal double-strand DNA breaks in receptor-positive tumor cells while relatively sparing surrounding tissue. SSTR2 expression, confirmed by somatostatin-receptor imaging…

FDA Indications

• Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs, in adults (FDA approval 2018, based on NETTER-1)
• Somatostatin receptor-positive GEP-NETs in pediatric patients ≥12 years

Common Side Effects

• Nausea and vomiting (largely related to the amino acid co-infusion)
• Fatigue
• Lymphopenia and other cytopenias
• Decreased appetite
• Abdominal pain and diarrhea
• Elevated liver enzymes and hyperglycemia

Clinical Pearl

Lutathera is a targeted internal-radiation therapy, not conventional chemotherapy: its whole benefit depends on documented SSTR2 positivity on somatostatin-receptor PET, so imaging selection is mandatory. The renal-protective amino acid co-infusion is non-negotiable — it drives most of the nausea but prevents the dose-limiting nephrotoxicity that ended earlier PRRT programs. Long-acting somatostatin analogs must be paused before dosing (they block the receptor) but short-acting octreotide is…

Related Therapies & Mechanisms

• Lutetium-177 DOTATATE (Lutathera) — Radiopharmaceutical · NET
• Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) — Radiopharmaceutical
• Radium-223 Dichloride (Xofigo) — Radiopharmaceutical
• Capecitabine (Xeloda) — NET